CLAIMS:

1. Use of an effective amount of Calebin A for the manufacture of a medicament for inhibiting adipogenesis.

2. Use of an effective amount of Calebin A for the manufacture of a medicament for inhibiting leptin expression in adipocytes.

3. Use of an effective amount of Calebin A for the manufacture of a medicament for increasing expression of adiponectin in adipocytes.

4. Use of an effective amount of Calebin A for the manufacture of a medicament for inhibiting obesity induced pro-inflammatory cytokines in adipocytes.

5. The use according to claim 4, wherein the pro-inflammatory cytokine is Tumor Necrosis Factor-α (TNF-α).

6. The use according to claim 4, wherein the pro-inflammatory cytokine is Interleukin-6 (IL-6).

7. Use of an effective amount of Calebin A for the manufacture of a medicament for reducing obesity induced systemic expression of pro-inflammatory cytokines.

8. The use according to claim 7, wherein the pro-inflammatory cytokine is Tumor Necrosis Factor-α (TNF-α).

9. The use according to claim 7, wherein the pro-inflammatory cytokine is Interleukin-6 (IL-6).

10. The use according to claim 7, wherein the pro-inflammatory cytokine is Interleukin-1β (IL-1β).

11. Use of an effective amount of Calebin-A for the manufacture of a medicament for obesity management.